Difficulty: Medium
Average Score: 84%
Practice
Tolcapone is an antiparkinsonian agent that inhibits which of the following enzymes in brain?
Correct answer
A
Rationale
In this CNS stimulants drugs pharmacology quiz question, the correct answer is A) Catechol-O-methyltransferase (COMT). Tolcapone is an antiparkinsonian agent that works by inhibiting the enzyme COMT.
COMT is responsible for the breakdown of catecholamines, including dopamine, in the brain. By inhibiting COMT, tolcapone helps to increase dopamine levels in the brain, which is beneficial in managing Parkinson's disease symptoms.
Option B) Tyrosine hydroxylase (TH) is incorrect because TH is an enzyme involved in the production of dopamine, not its breakdown. Inhibiting TH would actually decrease dopamine production.
Option C) Monoamine oxidase-B (MAO-B) is incorrect because MAO-B is involved in the breakdown of dopamine, but tolcapone does not inhibit this enzyme.
Option D) Monoamine oxidase-A (MAO-A) is incorrect because MAO-A is involved in the breakdown of serotonin and norepinephrine, not dopamine.
Understanding the specific enzymes targeted by drugs is crucial in pharmacology to predict their effects and potential side effects. In the context of CNS stimulants and antiparkinsonian agents, knowing how these drugs interact with enzymes like COMT helps in optimizing treatment strategies for patients with neurological disorders.
COMT is responsible for the breakdown of catecholamines, including dopamine, in the brain. By inhibiting COMT, tolcapone helps to increase dopamine levels in the brain, which is beneficial in managing Parkinson's disease symptoms.
Option B) Tyrosine hydroxylase (TH) is incorrect because TH is an enzyme involved in the production of dopamine, not its breakdown. Inhibiting TH would actually decrease dopamine production.
Option C) Monoamine oxidase-B (MAO-B) is incorrect because MAO-B is involved in the breakdown of dopamine, but tolcapone does not inhibit this enzyme.
Option D) Monoamine oxidase-A (MAO-A) is incorrect because MAO-A is involved in the breakdown of serotonin and norepinephrine, not dopamine.
Understanding the specific enzymes targeted by drugs is crucial in pharmacology to predict their effects and potential side effects. In the context of CNS stimulants and antiparkinsonian agents, knowing how these drugs interact with enzymes like COMT helps in optimizing treatment strategies for patients with neurological disorders.